Advertisement

BioDrugs

, Volume 33, Issue 1, pp 61–78 | Cite as

Monoclonal Antibodies for Multiple Sclerosis: An Update

  • Jonas Graf
  • Orhan Aktas
  • Konrad Rejdak
  • Hans-Peter HartungEmail author
Review Article

Abstract

The use of monoclonal antibodies in multiple sclerosis (MS) patients is in a transitional period. Studies regarding well-established, effective antibodies such as natalizumab and alemtuzumab focus more and more on long-term efficacy and safety, risk management, and treating complications. Primary progressive MS, a disease that was long considered to be unmodifiable, is currently in focus following ocrelizumab being approved as the first drug with a proven beneficial effect on the disease course. Conversely, post-marketing safety mechanisms have also proven to function as daclizumab has been suspended after a series of relevant serious adverse events. Currently, new therapies are emerging that promise more convenience and an improved safety profile (ofatumumab) or remyelinating potential with clinical improvement (opicinumab). While it is very unlikely that monoclonal antibodies will ever cure MS, they have become very valuable therapeutic tools to better patient outcomes. This review focuses on developments of monoclonal antibodies used in the past, present, and near future in MS patients.

Notes

Compliance with Ethical Standards

Funding

No funding was received for the preparation of this review.

Conflict of interest

Jonas Graf received travel/meeting/accommodation reimbursements from Biogen, and Merck Serono. Orhan Aktas received, with approval of the Rector of Heinrich-Heine-University, grants from the German Research Foundation (DFG) and the German Ministry for Education and Research (BMBF) as part of the German Competence Network Multiple Sclerosis (Kompetenznetz Multiple Sklerose (KKNMS); for NEMOS (Neuromyelitis optica Studiengruppe, German Neuromyelitis Optica Study group) NationNMO-PAT FKZ 01GI1602B), the Eugène Devic European Network (EU-FP7), and honoraria and travel/accommodation/meeting expenses from Almirall, Bayer, Biogen, Medimmune, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. Konrad Rejdak has no conflicts of interest to declare. Hans-Peter Hartung received, with approval of the Rector of Heinrich-Heine-University and the CEO of University of Düsseldorf Hospital, honoraria for consulting, serving on steering committees, and speaking from Biogen, CSL Behring, Geneuro, Genzyme, LFB, Medimmune, Merck, Novartis, Octapharma, Opexa, Receptos/Celgene, Roche, Sanofi, and Teva.

References

  1. 1.
    Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018;391:1622–36.  https://doi.org/10.1016/S0140-6736(18)30481-1.CrossRefPubMedGoogle Scholar
  2. 2.
    Lublin FD. New multiple sclerosis phenotypic classification. Eur Neurol. 2014;72(Suppl 1):1–5.  https://doi.org/10.1159/000367614.CrossRefPubMedGoogle Scholar
  3. 3.
    Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.  https://doi.org/10.1212/WNL.0000000000000560.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:789–800.  https://doi.org/10.1212/WNL.0000000000005345.CrossRefPubMedGoogle Scholar
  5. 5.
    Rae-Grant A, Day GS, Marrie RA, Rabinstein A, Cree BAC, Gronseth GS, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–88.  https://doi.org/10.1212/WNL.0000000000005347.CrossRefPubMedGoogle Scholar
  6. 6.
    Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10:183–203.  https://doi.org/10.1080/19420862.2018.1415671.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518.  https://doi.org/10.1136/bmj.i3518.CrossRefPubMedGoogle Scholar
  8. 8.
    Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol Scand. 2017;136:168–86.  https://doi.org/10.1111/ane.12712.CrossRefGoogle Scholar
  9. 9.
    Winkelmann A, Loebermann M, Reisinger EC, Hartung H-P, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12:217–33.  https://doi.org/10.1038/nrneurol.2016.21.CrossRefPubMedGoogle Scholar
  10. 10.
    Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23.  https://doi.org/10.1056/NEJMoa020696.CrossRefPubMedGoogle Scholar
  11. 11.
    Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.  https://doi.org/10.1056/NEJMoa044397.CrossRefPubMedGoogle Scholar
  12. 12.
    Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8:254–60.  https://doi.org/10.1016/S1474-4422(09)70021-3.CrossRefPubMedGoogle Scholar
  13. 13.
    Oshima Y, Tanimoto T, Yuji K, Tojo A. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler. 2018.  https://doi.org/10.1177/1352458518786075.CrossRefPubMedGoogle Scholar
  14. 14.
    Biogen. Biogen internal data. Safety update on natalizumab; September 2018. www.tysabri.de. Accessed 10 Dec 2018.
  15. 15.
    Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. Efficacy and safety of natalizumab in multiple sclerosis: Interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190–7.  https://doi.org/10.1136/jnnp-2013-306936.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lorefice L, Fenu G, Gerevini S, Frau J, Coghe G, Barracciu MA, et al. PML in a person with multiple sclerosis: is teriflunomide the felon? Neurology. 2018;90:83–5.  https://doi.org/10.1212/WNL.0000000000004804.CrossRefPubMedGoogle Scholar
  17. 17.
    Bauer J, Gold R, Adams O, Lassmann H. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS). Acta Neuropathol. 2015;130:751–64.  https://doi.org/10.1007/s00401-015-1471-7.CrossRefPubMedGoogle Scholar
  18. 18.
    Major EO, Yousry TA, Clifford DB. Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. Lancet Neurol. 2018;17:467–80.  https://doi.org/10.1016/S1474-4422(18)30040-1.CrossRefPubMedGoogle Scholar
  19. 19.
    Ho P-R, Koendgen H, Campbell N, Haddock B, Richman S, Chang I. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16:925–33.  https://doi.org/10.1016/S1474-4422(17)30282-X.CrossRefPubMedGoogle Scholar
  20. 20.
    Warnke C, Ramanujam R, Plavina T, Bergström T, Goelz S, Subramanyam M, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry. 2013;84:1199–205.  https://doi.org/10.1136/jnnp-2012-304332.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802–12.  https://doi.org/10.1002/ana.24286.CrossRefPubMedGoogle Scholar
  22. 22.
    Plavina T, Muralidharan KK, Kuesters G, Mikol D, Evans K, Subramanyam M, et al. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. Neurology. 2017;89:1584–93.  https://doi.org/10.1212/WNL.0000000000004485.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bianco A, Rossini PM, Mirabella M. Moving to fingolimod from natalizumab in multiple sclerosis: the ENIGM is not solved. JAMA Neurol. 2014;71:924–5.  https://doi.org/10.1001/jamaneurol.2014.1135.CrossRefPubMedGoogle Scholar
  24. 24.
    Derfuss T, Kovarik JM, Kappos L, Savelieva M, Chhabra R, Thakur A, et al. α4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurol Neuroimmunol Neuroinflamm. 2017;4:e388.  https://doi.org/10.1212/NXI.0000000000000388.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80:1430–8.  https://doi.org/10.1212/WNL.0b013e31828c2fa1.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. J Neurol Neurosurg Psychiatry. 2018.  https://doi.org/10.1136/jnnp-2018-318261.CrossRefPubMedGoogle Scholar
  27. 27.
    Peters J, Williamson E. Natalizumab therapy is associated with changes in serum JC virus antibody indices over time. J Neurol. 2017;264:2409–12.  https://doi.org/10.1007/s00415-017-8643-4.CrossRefPubMedGoogle Scholar
  28. 28.
    Koolaji S, Allahabadi NS, Ahmadi A, Eskandarieh S, Moghadasi AN, Azimi AR, et al. Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence. J Neurovirol. 2018;24(5):570–6.  https://doi.org/10.1007/s13365-018-0646-0.CrossRefPubMedGoogle Scholar
  29. 29.
    van Kempen Z, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Mult Scler. 2017;23:995–9.  https://doi.org/10.1177/1352458516684023.CrossRefPubMedGoogle Scholar
  30. 30.
    Fissolo N, Pignolet B, Matute-Blanch C, Triviño JC, Miró B, Mota M, et al. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. Ann Neurol. 2017;82:186–95.  https://doi.org/10.1002/ana.24987.CrossRefPubMedGoogle Scholar
  31. 31.
    Antoniol C, Stankoff B. Immunological markers for PML prediction in MS patients treated with natalizumab. Front Immunol. 2014;5:668.  https://doi.org/10.3389/fimmu.2014.00668.CrossRefPubMedGoogle Scholar
  32. 32.
    Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81:865–71.  https://doi.org/10.1212/WNL.0b013e3182a351fb.CrossRefPubMedGoogle Scholar
  33. 33.
    Lieberman LA, Zeng W, Singh C, Wang W, Otipoby KL, Loh C, et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology. 2016;86:375–81.  https://doi.org/10.1212/WNL.0000000000002314.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Scarpazza C, Prosperini L, De Rossi N, Moiola L, Sormani MP, Gerevini S, Capra R. To do or not to do? Plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. Ann Neurol. 2017;82:697–705.  https://doi.org/10.1002/ana.25070.CrossRefPubMedGoogle Scholar
  35. 35.
    Landi D, de Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, et al. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. Neurology. 2017;88:1144–52.  https://doi.org/10.1212/WNL.0000000000003740.CrossRefPubMedGoogle Scholar
  36. 36.
    Yamout BI, Sahraian MA, Ayoubi NE, Tamim H, Nicolas J, Khoury SJ, et al. Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord. 2018;24:113–6.  https://doi.org/10.1016/j.msard.2018.06.015.CrossRefPubMedGoogle Scholar
  37. 37.
    Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17:405–15.  https://doi.org/10.1016/S1474-4422(18)30069-3.CrossRefPubMedGoogle Scholar
  38. 38.
    Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis. J Immunol. 2013;191:5867–74.  https://doi.org/10.4049/jimmunol.1301926.CrossRefPubMedGoogle Scholar
  39. 39.
    Hartung H-P, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21:22–34.  https://doi.org/10.1177/1352458514549398.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Coles AJ, Compston DAS, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359:1786–801.  https://doi.org/10.1056/NEJMoa0802670.CrossRefPubMedGoogle Scholar
  41. 41.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28.  https://doi.org/10.1016/S0140-6736(12)61769-3.CrossRefPubMedGoogle Scholar
  42. 42.
    Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39.  https://doi.org/10.1016/S0140-6736(12)61768-1.CrossRefPubMedGoogle Scholar
  43. 43.
    Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol. 2011;10:338–48.  https://doi.org/10.1016/S1474-4422(11)70020-5.CrossRefPubMedGoogle Scholar
  44. 44.
    Hartung H-P, Aktas O. Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol. 2011;10:293–5.  https://doi.org/10.1016/S1474-4422(11)70043-6.CrossRefPubMedGoogle Scholar
  45. 45.
    Havrdova E, Arnold DL, Cohen JA, Hartung H-P, Fox EJ, Giovannoni G, et al. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology. 2017;89:1107–16.  https://doi.org/10.1212/WNL.0000000000004313.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung H-P, Havrdova E, et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology. 2017;89:1117–26.  https://doi.org/10.1212/WNL.0000000000004354.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Giovannoni G, Cohen JA, Coles AJ, Hartung H-P, Havrdova E, Selmaj KW, et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology. 2016;87:1985–92.  https://doi.org/10.1212/WNL.0000000000003319.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurol. 2017;16:271–81.  https://doi.org/10.1016/S1474-4422(17)30007-8.CrossRefPubMedGoogle Scholar
  49. 49.
    Lizak N, Lugaresi A, Alroughani R, Lechner-Scott J, Slee M, Havrdova E, et al. Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. J Neurol Neurosurg Psychiatry. 2017;88:196–203.  https://doi.org/10.1136/jnnp-2016-313976.CrossRefPubMedGoogle Scholar
  50. 50.
    Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, et al. Disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis: a cost-utility analysis. CNS Drugs. 2018.  https://doi.org/10.1007/s40263-018-0566-9.CrossRefPubMedGoogle Scholar
  51. 51.
    Haghikia A, Dendrou CA, Schneider R, Grüter T, Postert T, Matzke M, et al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol. 2017;16:104–6.  https://doi.org/10.1016/S1474-4422(16)30382-9.CrossRefPubMedGoogle Scholar
  52. 52.
    Wehrum T, Beume L-A, Stich O, Mader I, Mäurer M, Czaplinski A, et al. Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis. Neurology. 2018;90:e601–5.  https://doi.org/10.1212/WNL.0000000000004950.CrossRefPubMedGoogle Scholar
  53. 53.
    Barton J, Hardy TA, Riminton S, Reddel SW, Barnett Y, Coles A, Barnett MH. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology. 2017;88:1004–6.  https://doi.org/10.1212/WNL.0000000000003694.CrossRefPubMedGoogle Scholar
  54. 54.
    Pfeuffer S, Beuker C, Ruck T, Lenze F, Wiendl H, Melzer N, Meuth SG. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. Neurology. 2016;87:2380–1.  https://doi.org/10.1212/WNL.0000000000003379.CrossRefPubMedGoogle Scholar
  55. 55.
    Sauer E-M, Schliep S, Manger B, Lee D-H, Linker RA. Microscopic polyangiitis after alemtuzumab treatment in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e488.  https://doi.org/10.1212/NXI.0000000000000488.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Graf J, Ringelstein M, Lepka K, Schaller J, Quack H, Hartung H-P, et al. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Mult Scler. 2018;24(13):1776–8.  https://doi.org/10.1177/1352458518771276.CrossRefPubMedGoogle Scholar
  57. 57.
    Willis MD, Hope-Gill B, Flood-Page P, Joseph F, Needham E, Jones J, et al. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Mult Scler. 2018;24(13):1779–82.  https://doi.org/10.1177/1352458518790391.CrossRefPubMedGoogle Scholar
  58. 58.
    Pfeuffer S. Sarcoidosis following alemtuzumab treatment: autoimmunity mediated by T cells and interferon-γ. Mult Scler. 2018;24(13):1783–4.  https://doi.org/10.1177/1352458518804124.CrossRefPubMedGoogle Scholar
  59. 59.
    Leussink VI, Reifenberger J, Hartung H-P. Case of alopecia universalis associated with alemtuzumab treatment in MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e454.  https://doi.org/10.1212/NXI.0000000000000454.CrossRefGoogle Scholar
  60. 60.
    Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, et al. Vitiligo after alemtuzumab treatment: secondary autoimmunity is not all about B cells. Neurology. 2018.  https://doi.org/10.1212/WNL.0000000000006648.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Rau D, Lang M, Harth A, Naumann M, Weber F, Tumani H, et al. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis—report of two cases. Int J Mol Sci. 2015;16:14669–76.  https://doi.org/10.3390/ijms160714669.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Canham LJW, Manara A, Fawcett J, Rolinski M, Mortimer A, Inglis KEA, et al. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2018;24:38–41.  https://doi.org/10.1016/j.msard.2018.05.014.CrossRefPubMedGoogle Scholar
  63. 63.
    Meunier B, Rico A, Seguier J, Boutiere C, Ebbo M, Harle JR, et al. Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. Mult Scler. 2018;24:811–3.  https://doi.org/10.1177/1352458517729766.CrossRefPubMedGoogle Scholar
  64. 64.
    Saarela M, Senthil K, Jones J, Tienari PJ, Soilu-Hänninen M, Airas L, et al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018;90:849–51.  https://doi.org/10.1212/WNL.0000000000005420.CrossRefPubMedGoogle Scholar
  65. 65.
    Brownlee WJ, Chataway J. Opportunistic infections after alemtuzumab: new cases of norcardial infection and cytomegalovirus syndrome. Mult Scler. 2017;23:876–7.  https://doi.org/10.1177/1352458517693440.CrossRefPubMedGoogle Scholar
  66. 66.
    Clerico M, de Mercanti S, Artusi CA, Durelli L, Naismith RT. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler. 2017;23:874–6.  https://doi.org/10.1177/1352458516688350.CrossRefPubMedGoogle Scholar
  67. 67.
    Blasco MR, Ramos A, Malo CG, García-Merino A. Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis. J Neurol. 2017;264:168–9.  https://doi.org/10.1007/s00415-016-8306-x.CrossRefPubMedGoogle Scholar
  68. 68.
    Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, et al. Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult Scler. 2018.  https://doi.org/10.1177/1352458518796675.CrossRefPubMedGoogle Scholar
  69. 69.
    Pariani N, Willis M, Muller I, Healy S, Nasser T, McGowan A, et al. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. J Clin Endocrinol Metab. 2018;103:3010–8.  https://doi.org/10.1210/jc.2018-00359.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Steinman L. Induction of new autoimmune diseases after alemtuzumab therapy for multiple sclerosis: learning from adversity. JAMA Neurol. 2017;74:907–8.  https://doi.org/10.1001/jamaneurol.2017.0325.CrossRefPubMedGoogle Scholar
  71. 71.
    Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, et al. Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Ann Clin Transl Neurol. 2017;4:909–14.  https://doi.org/10.1002/acn3.491.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Guarnera C, Bramanti P, Mazzon E. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis. Ther Clin Risk Manag. 2017;13:871–9.  https://doi.org/10.2147/TCRM.S134398.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics. 2013;10:55–67.  https://doi.org/10.1007/s13311-012-0147-4.CrossRefPubMedGoogle Scholar
  74. 74.
    Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, et al. Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2015;373:1418–28.  https://doi.org/10.1056/NEJMoa1501481.CrossRefPubMedGoogle Scholar
  75. 75.
    Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue E-W, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–75.  https://doi.org/10.1016/S0140-6736(12)62190-4.CrossRefPubMedGoogle Scholar
  76. 76.
    Kappos L, Havrdova E, Giovannoni G, Khatri BO, Gauthier SA, Greenberg SJ, et al. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. Mult Scler. 2017;23:1736–47.  https://doi.org/10.1177/1352458516683266.CrossRefPubMedGoogle Scholar
  77. 77.
    Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: results from the DECIDE study. Mult Scler. 2018;24:795–804.  https://doi.org/10.1177/1352458517707345.CrossRefPubMedGoogle Scholar
  78. 78.
    Lancet T. End of the road for daclizumab in multiple sclerosis. Lancet. 2018;391:1000.  https://doi.org/10.1016/S0140-6736(18)30565-8.CrossRefGoogle Scholar
  79. 79.
    Devlin M, Swayne A, Newman M, O’Gorman C, Brown H, Ong B, et al. A case of immune-mediated encephalitis related to daclizumab therapy. Mult Scler. 2018.  https://doi.org/10.1177/1352458518792403.CrossRefPubMedGoogle Scholar
  80. 80.
    Williams T, Chataway J. Immune-mediated encephalitis with daclizumab: the final nail. Mult Scler. 2018.  https://doi.org/10.1177/1352458518791374.CrossRefPubMedGoogle Scholar
  81. 81.
    European Medical Agency, Pharmacovigilance Risk Assessment Committee (PRAC). Assessment report on provisional measures, Procedure under Article 20 of Regulation (EC) No 726/2004 resulting from pharmacovigilance data pharmacovigilance data Zinbryta, Procedure number: EMEA/H/A-20/1462/C/003862/0018; 2018. https://www.ema.europa.eu/documents/referral/zinbryta-article-20-referral-prac-assessment-report_en.pdf. Accessed 20 Aug 2018.
  82. 82.
    Luessi F, Engel S, Spreer A, Bittner S, Zipp F. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm. 2018;5:e481.  https://doi.org/10.1212/NXI.0000000000000481.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Krueger JG, Kircik L, Hougeir F, Friedman A, You X, Lucas N, et al. Cutaneous adverse events in the randomized, double-blind, active-comparator DECIDE study of daclizumab high-yield process versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. Adv Ther. 2016;33:1231–45.  https://doi.org/10.1007/s12325-016-0353-2.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Cortese I, Ohayon J, Fenton K, Lee C-C, Raffeld M, Cowen EW, et al. Cutaneous adverse events in multiple sclerosis patients treated with daclizumab. Neurology. 2016;86:847–55.  https://doi.org/10.1212/WNL.0000000000002417.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Rauer S, Stork L, Urbach H, Stathi A, Marx A, Süß P, et al. Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy. Neurology. 2018;91:e359–63.  https://doi.org/10.1212/WNL.0000000000005854.CrossRefPubMedGoogle Scholar
  86. 86.
    Franks SE, Getahun A, Hogarth PM, Cambier JC. Targeting B cells in treatment of autoimmunity. Curr Opin Immunol. 2016;43:39–45.  https://doi.org/10.1016/j.coi.2016.09.003.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, et al. Features of human CD3+CD20+ T cells. J Immunol. 2016;197:1111–7.  https://doi.org/10.4049/jimmunol.1600089.CrossRefPubMedGoogle Scholar
  88. 88.
    Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193:580–6.  https://doi.org/10.4049/jimmunol.1400118.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Wilk E, Witte T, Marquardt N, Horvath T, Kalippke K, Scholz K, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheumatol. 2009;60:3563–71.  https://doi.org/10.1002/art.24998.CrossRefGoogle Scholar
  90. 90.
    Stüve O, Cepok S, Elias B, Saleh A, Hartung H-P, Hemmer B, Kieseier BC. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol. 2005;62:1620–3.  https://doi.org/10.1001/archneur.62.10.1620.CrossRefPubMedGoogle Scholar
  91. 91.
    Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons J-A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63–70.  https://doi.org/10.1016/j.jneuroim.2006.06.029.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.  https://doi.org/10.1056/NEJMoa0706383.CrossRefPubMedGoogle Scholar
  93. 93.
    Alcalá C, Gascón F, Pérez-Miralles F, Gil-Perotín S, Navarré A, Boscá I, et al. Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study. J Neurol. 2018;265:1690–7.  https://doi.org/10.1007/s00415-018-8899-3.CrossRefPubMedGoogle Scholar
  94. 94.
    Scotti B, Disanto G, Sacco R, Guigli M, Zecca C, Gobbi C. Effectiveness and safety of rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS One. 2018;13:e0197415.  https://doi.org/10.1371/journal.pone.0197415.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, et al. Efficacy of rituximab in refractory RRMS. Mult Scler. 2018.  https://doi.org/10.1177/1352458518772748.CrossRefPubMedGoogle Scholar
  96. 96.
    Granqvist M, Boremalm M, Poorghobad A, Svenningsson A, Salzer J, Frisell T, Piehl F. Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis. JAMA Neurol. 2018;75:320–7.  https://doi.org/10.1001/jamaneurol.2017.4011.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Spelman T, Frisell T, Piehl F, Hillert J. Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry. Mult Scler. 2018;24:1087–95.  https://doi.org/10.1177/1352458517713668.CrossRefPubMedGoogle Scholar
  98. 98.
    Memon AB, Javed A, Caon C, Srivastawa S, Bao F, Bernitsas E, et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One. 2018;13:e0190425.  https://doi.org/10.1371/journal.pone.0190425.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, et al. Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 2016;87:2074–81.  https://doi.org/10.1212/WNL.0000000000003331.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Hawker K, O’Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–71.  https://doi.org/10.1002/ana.21867.CrossRefPubMedGoogle Scholar
  101. 101.
    Hartung H-P, Aktas O. Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope. Ann Neurol. 2009;66:429–32.  https://doi.org/10.1002/ana.21880.CrossRefPubMedGoogle Scholar
  102. 102.
    Mitka M. FDA: increased HBV reactivation risk with ofatumumab or rituximab. JAMA. 2013;310:1664.  https://doi.org/10.1001/jama.2013.281115.CrossRefPubMedGoogle Scholar
  103. 103.
    Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, et al. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: the Preblin study. PLoS One. 2017;12:e0184550.  https://doi.org/10.1371/journal.pone.0184550.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, et al. Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies. Mult Scler. 2018;24(9):1224–33.  https://doi.org/10.1177/1352458517720044.CrossRefPubMedGoogle Scholar
  105. 105.
    Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40.  https://doi.org/10.1182/blood-2008-10-186999.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Tallantyre EC, Whittam DH, Jolles S, Paling D, Constantinesecu C, Robertson NP, et al. Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. J Neurol. 2018;265:1115–22.  https://doi.org/10.1007/s00415-018-8812-0.CrossRefPubMedPubMedCentralGoogle Scholar
  107. 107.
    Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy—rare but there! Leuk Lymphoma. 2009;50:1083–95.  https://doi.org/10.1080/10428190902934944.CrossRefPubMedGoogle Scholar
  108. 108.
    Rissanen E, Remes K, Airas L. Severe neutropenia after rituximab-treatment of multiple sclerosis. Mult Scler Relat Disord. 2018;20:3–5.  https://doi.org/10.1016/j.msard.2017.12.005.CrossRefPubMedGoogle Scholar
  109. 109.
    Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221–34.  https://doi.org/10.1056/NEJMoa1601277.CrossRefPubMedGoogle Scholar
  110. 110.
    Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–20.  https://doi.org/10.1056/NEJMoa1606468.CrossRefPubMedGoogle Scholar
  111. 111.
    Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378:1779–87.  https://doi.org/10.1016/S0140-6736(11)61649-8.CrossRefPubMedGoogle Scholar
  112. 112.
    Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung H-P, Kappos L, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018;4:2055217318760642.  https://doi.org/10.1177/2055217318760642.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Hauser S. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Platform presentation number S36.001. AAN Annual Meeting; 2018. http://n.neurology.org/content/90/15_Supplement/S36.001. Accessed 20 Aug 2018.
  114. 114.
    Sorensen PS, Lisby S, Grove R, Derosier F, Shackelford S, Havrdova E, et al. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study. Neurology. 2014;82:573–81.  https://doi.org/10.1212/WNL.0000000000000125.CrossRefPubMedGoogle Scholar
  115. 115.
    Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90:e1805–14.  https://doi.org/10.1212/WNL.0000000000005516.CrossRefPubMedPubMedCentralGoogle Scholar
  116. 116.
    Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8:745–51.  https://doi.org/10.1038/nn1460.CrossRefPubMedGoogle Scholar
  117. 117.
    Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol. 2009;65:304–15.  https://doi.org/10.1002/ana.21581.CrossRefPubMedGoogle Scholar
  118. 118.
    Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13:1228–33.  https://doi.org/10.1038/nm1664.CrossRefPubMedGoogle Scholar
  119. 119.
    Aktas O, Albrecht P, Hartung H-P. Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis: update on current trials and perspectives. Curr Opin Neurol. 2016;29:199–204.  https://doi.org/10.1097/WCO.0000000000000327.CrossRefPubMedGoogle Scholar
  120. 120.
    Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189–99.  https://doi.org/10.1016/S1474-4422(16)30377-5.CrossRefPubMedGoogle Scholar
  121. 121.
    Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ, et al. Predictors of response to opicinumab in acute optic neuritis. Ann Clin Transl Neurol. 2018;41:1017.  https://doi.org/10.1002/acn3.620.CrossRefGoogle Scholar
  122. 122.
    Ranger A, Ray S, Szak S, Dearth A, Allaire N, Murray R, et al. Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies. Neurol Neuroimmunol Neuroinflamm. 2018;5:e417.  https://doi.org/10.1212/NXI.0000000000000417.CrossRefPubMedGoogle Scholar
  123. 123.
    Kremer D, Göttle P, Hartung H-P, Küry P. Pushing forward: remyelination as the new frontier in CNS diseases. Trends Neurosci. 2016;39:246–63.  https://doi.org/10.1016/j.tins.2016.02.004.CrossRefPubMedGoogle Scholar
  124. 124.
    Moccia M, de Stefano N, Barkhof F. Imaging outcome measures for progressive multiple sclerosis trials. Mult Scler. 2017;23:1614–26.  https://doi.org/10.1177/1352458517729456.CrossRefPubMedPubMedCentralGoogle Scholar
  125. 125.
    Šega-Jazbec S, Barun B, Horvat Ledinek A, Fabekovac V, Krbot Skorić M, Habek M. Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis. Mult Scler Relat Disord. 2017;17:151–3.  https://doi.org/10.1016/j.msard.2017.07.019.CrossRefPubMedGoogle Scholar
  126. 126.
    Fabian M. Pregnancy in the setting of multiple sclerosis. Continuum (Minneap Minn). 2016;22:837–50.  https://doi.org/10.1212/CON.0000000000000328.CrossRefGoogle Scholar
  127. 127.
    Voskuhl R, Momtazee C. Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding. Neurotherapeutics. 2017;14:974–84.  https://doi.org/10.1007/s13311-017-0562-7.CrossRefPubMedPubMedCentralGoogle Scholar
  128. 128.
    Houtchens MK, Edwards NC, Phillips AL. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology. 2018;91:e1570–8.  https://doi.org/10.1212/WNL.0000000000006382.CrossRefPubMedPubMedCentralGoogle Scholar
  129. 129.
    European Medical Agency. Tysabri summary of product characteristics; 2018. https://ec.europa.eu/health/documents/community-register/2018/20180802142037/anx_142037_en.pdf. Accessed 20 Nov 2018.
  130. 130.
    European Medical Agency. Lemtrada summary of product characteristics; 2018. https://www.ema.europa.eu/documents/product-information/lemtrada-epar-product-information_en.pdf. Accessed 20 Nov 2018.
  131. 131.
    European Medical Agency. Ocrevus summary of product characteristics; 2018. https://www.ema.europa.eu/documents/product-information/ocrevus-epar-product-information_en.pdf. Accessed 20 Nov 2018.
  132. 132.
    Trojano M, Tintore M, Montalban X, Hillert J, Kalincik T, Iaffaldano P, et al. Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat Rev Neurol. 2017;13:105–18.  https://doi.org/10.1038/nrneurol.2016.188.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Neurology, University HospitalMedical Faculty Heinrich-Heine-UniversityDüsseldorfGermany
  2. 2.Department of NeurologyMedical University of LublinLublinPoland

Personalised recommendations